Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Neurocrine
Company Location: SAN DIEGO CA 92130
Company CEO: Kevin C. Gorman
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Multiple Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NBI-5788-0201 | P2 |
Completed |
Multiple Sclerosis |
None |